Alterity Therapeutics (ATHE) Shares Outstanding (Diluted Average) (2016 - 2025)

Alterity Therapeutics' Shares Outstanding (Diluted Average) history runs 10 years deep, the most recent figure standing at $4.1 billion for Q2 2025.

• In Q2 2025, Shares Outstanding (Diluted Average) rose 70.37% year-over-year to $4.1 billion; the TTM figure through Jun 2025 stood at $4.1 billion (up 70.37% YoY), while the FY2025 annual figure was $4.1 billion, up 70.37% from the prior year.
• Shares Outstanding (Diluted Average) was $4.1 billion for Q2 2025 at Alterity Therapeutics, up from $2.4 billion in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $4.1 billion in Q2 2025 to a low of $1.3 billion in Q2 2021.
• Historically, Shares Outstanding (Diluted Average) has averaged $2.2 billion across 5 years, with a median of $1.7 billion in 2022.
• The sharpest annual moves came in 2021 and 2023: Shares Outstanding (Diluted Average) jumped 122.79% in 2021, then declined 5.84% in 2023.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $1.3 billion in 2021, then jumped by 31.89% to $1.7 billion in 2022, then slipped by 5.84% to $1.6 billion in 2023, then jumped by 48.19% to $2.4 billion in 2024, then jumped by 70.37% to $4.1 billion in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $4.1 billion (Q2 2025), $2.4 billion (Q2 2024), and $1.6 billion (Q2 2023), per Business Quant data.